So we are in the pullback to the breakout levels and the sector has some decision making to do. Either this level holds and we confirm the breakout or we make our way lower and the “breakout” looks like a blow off top. A breakdown would not be a great signal (obviously) but this would […]
May 12th Biotech Update
We had our breakout and run yesterday and while there is little follow through today, I suspect that we get a continuation. It appears that the breakout is happening but the confirmation still needs to occur. The final signal would be to test the old resistance level with a selloff and to rally off the […]
April 20th Biotech (and MLP) Update
So it looked like last week finally decided the next move would be higher but this morning we start with some weakness. I would not be surprised, however, to see the market to reverse during the day. I saw an analysis that showed almost all of the downside on the selloff the past couple months […]
February 13th Biotech Update
The sector continues to do well this week on not necessarily all positive news. My refrain will continue to be that we are range bound until proven otherwise and so it should not surprise anyone that is still my position. 1. On the positive side, EXEL announced pretty strong numbers and one could argue that […]
August 4 Biotech Update
I am back from my last trip of the summer and to be honest it is going to take me the weekend to catch up on all the news. That being said there are a couple of points I can make that are essentially the frame I will use to look at the recent news. […]
February 1 Biotech Update
Different week but the same market. There remains a bias to the downside, although perhaps an optimist can see a slight outperformance of the sector. At the very least, it seems like the sector is not leading the market lower. We got some news this morning but the key this week will continue to be […]
September 28 Biotech Update
The market has been ugly and rough and at times like this you simply want to throw up your hands and walk away but this is where values develop, so it is worth staying engaged even if we are not at the bottom. I think it is a legitimate question as to whether we are […]
July 20 Biotech Update
There is some news this morning but nothing that in and of itself is likely to move the sector. On the other hand, the news has generally been positive, so there is nothing to change the momentum to the upside. It is nice to see a week begin without a major macro discussion. Perhaps this […]
Catalyst Watch – Vol. 3, Edition 3 (1/18/15)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: AMPE: Ampio has […]
December 1 Bitoech Update
Markets are weak and the biotech sector is moving with it and it appears that small cap and momentum plays are being most affected (large caps seem to be holding up fairly well). The market probably needs to consolidate its recent move as do a lot of biotechs but the wild cards this month are […]
Catalyst Watch – Vol. 2, Edition 26 (9/9/14)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: AEZS: PDUFA is […]
September 3 Biotech Update
So the market continues to make marginal highs and essentially is drifting higher as the path of least resistance remains slightly higher each day. At his point, however, we cannot discount the possibility of a correction as a lot of stocks have had good runs. Trying to time when these corrections occur is losing game […]
Catalyst Watch – Vol. 2, Edition 24 (8/11/14)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: AEZS: PDUFA is […]
Catalyst Watch – Vol. 2, Edition 23 (7/29/14)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: AEZS: I continue […]
Catalyst Watch – Vol. 2, Edition 22 (7/7/14)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: Updates AEZS: I’m […]
Catalyst Watch – Vol. 2, Edition 19 (6/13/14)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: Updates CNAT: Holding […]
Catalyst Watch – Vol. 2, Edition 10 (4/4/14)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List – Update: CYTK: […]
March 26- Biotechs are Not Dead Yet
This is a better day but sellers still seem there but buying seems more concerted today. It appears that yesterday was the buyers dipping their toes in the water to make sure the coast was clear and today they seemed much more willing to put cash to work. As we saw with yesterday, however, the […]
January 23rd Biotech Update
The macro backdrop today was not great but the sector did better than I would have expected going into the day. That being said there is likely a correction coming so buying this dip might not be the best strategy. I am still mainly sitting on the sidelines on stocks I am watching waiting for […]
Preview of the 2013 ASCO GU Symposium
The 2013 ASCO Genitourinary Cancers Symposium provides an interdisciplinary forum to explore and discuss specific areas of research and clinical interest related to lysosomal diseases. With regards to clinical data presentations, all of the important clinical data will be released on Friday, February 15th. Abstracts can be searched with this link. The embargoes on abstract […]
